Debio 1453 is a FabI inhibitor specifically targeting N. gonorrhoeae developed in collaboration with Nobelex. This compound belongs to a family of narrow-spectrum antiobiotics that combines a very potent activity on pathogens of interest while reducing the selective pressure on other bacterial strains and sparing the microbiome.
November 8, 2019
Debiopharm progresses in their stand against drug-resistant N. gonorrhoeae with extended CARB-X funding of their Debio 1453 antibiotic program
July 25, 2017
Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea